Lilly starts a Phase 1b study of brenipatide in overweight and obesity

Eli Lilly has begun a Phase 1b clinical trial testing brenipatide, also known by its research code LY3537031, in people who are overweight or have obesity. The study, registered as NCT07476118 on ClinicalTrials.gov, started on March 18, 2026, and is designed to enroll about 150 participants ^[1].

The trial is titled "A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity," and it accepts healthy volunteers, meaning participants do not need to have diabetes or another diagnosed disease to take part ^[1]. Brenipatide is described as an incretin, the broad class of hormone-mimicking drugs that also includes semaglutide (sold as Ozempic, Wegovy, and Rybelsus) and tirzepatide (sold as Mounjaro and Zepbound) ^[1]. This is a Phase 1b pharmacodynamics study, an early-stage trial that looks at how the drug behaves in the body and what biological effects it produces, rather than testing how well it works against a disease over the long term.

Lilly has framed brenipatide as aimed at indications beyond the company's core obesity and diabetes programs, according to the study record ^[1]. The available registry information does not spell out what those other indications might be, what doses are being tested, how long the study will run, or when results are expected. Those specifics are not yet public.

Why it matters for patients

Brenipatide is a new molecule, not a version of semaglutide or tirzepatide, and it is very early in testing. A Phase 1b study like this one is meant to check safety and measure biological activity in a relatively small group of people, not to prove the drug helps with weight loss or any other condition. It will likely be years, if this drug moves forward at all, before it could become available by prescription.

For people currently using or considering GLP-1 medications such as Ozempic, Wegovy, Zepbound, Mounjaro, or Rybelsus, this study does not change anything about those existing options. It signals that Lilly, which already markets tirzepatide and is developing the oral pill orforglipron (Foundayo), continues to invest in additional incretin-based compounds. That could eventually mean more choices for patients, but nothing here indicates brenipatide is close to approval or even confirmed to be safe and effective for any use.

The fact that Lilly is testing this drug specifically for potential uses "beyond" obesity and diabetes suggests the company may be looking at other conditions where incretin biology plays a role. What those conditions are is not yet known from the public record ^[1].

What happens next

The study began enrolling on March 18, 2026 ^[1]. As an early-phase pharmacodynamics trial with about 150 participants, it is designed to gather safety and biological-activity data before Lilly would decide whether to advance brenipatide into larger trials ^[1]. No completion date, results timeline, or details about a broader Phase 2 or Phase 3 program have been published yet. Patients interested in following the drug's progress can watch for updates to the ClinicalTrials.gov record over time, since early-stage studies like this one often take a year or more to complete before any results are reported.